^
Association details:
| Biomarker: | ALK I1268L |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
Excerpt:
To validate ENU mutagenesis screening methodology at first, we explored crizotinib or alectinib-resistant ALK mutants using Ba/F3 cells expressing EML4-ALK-wild-type clonal cells#13. As the results, C1156Y, I1171T, F1174C/I/V, L1196M, and I1268L mutations in ALK were identified as crizotinib-resistant mutants.
DOI:
https://doi.org/10.1016/j.ebiom.2019.01.019
